Stratification of the minimal clinically important difference, substantial clinical benefit, and patient acceptable symptomatic state after total shoulder arthroplasty by implant type, preoperative diagnosis, and sex
Journal of Shoulder and Elbow Surgery · 2024-09 · 33 (9) · e492-e506
DOI: 10.1016/j.jse.2024.01.040 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Journal of Shoulder and Elbow Surgery, 2024-09. Verfasst von Ryan W Simovitch und 9 weiteren Autor:innen. Beteiligte Einrichtung: Hospital for Special Surgery, West Palm Beach, FL, USA. Hauptthemen laut MEDLINE: Arthroplasty, Replacement, Shoulder, Minimal Clinically Important Difference. Die Arbeit wurde bisher 51-mal zitiert (Crossref) und nennt 22 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND: Clinical significance, as opposed to statistical significance, has increasingly been utilized to evaluate outcomes after total shoulder arthroplasty (TSA). The purpose of this study was to identify thresholds of the minimal clinically important difference (MCID), substantial clinical benefit (SCB), and patient acceptable symptomatic state (PASS) for TSA outcome metrics and determine if these thresholds are influenced by prosthesis type (anatomic or reverse TSA), sex, or preoperative diagnosis. METHODS: A prospectively collected international multicenter database inclusive of 38 surgeons was queried for patients receiving a primary aTSA or rTSA between 2003 and 2021. Prospectively, outcome metrics including ASES, shoulder function score (SFS), SST, UCLA, Constant, VAS Pain, shoulder arthroplasty smart (SAS) score, forward flexion, abduction, external rotation, and internal rotation was recorded preoperatively and at each follow-up. A patient satisfaction question was administered at each follow-up. Anchor-based MCID, SCB, and PASS were calculated as defined previously overall and according to implant type, preoperative diagnosis, and sex. The percentage of patients achieving thresholds was also quantified. RESULTS: A total of 5851 total shoulder arthroplasties (TSAs) including aTSA (n = 2236) and rTSA (n = 3615) were included in the study cohort. The following were identified as MCID thresholds for the overall (aTSA + rTSA irrespective of diagnosis or sex) cohort: VAS Pain (-1.5), SFS (1.2), SST (2.1), Constant (7.2), ASES (13.9), UCLA (8.2), SPADI (-21.5), and SAS (7.3), Abduction (13°), Forward elevation (16°), External rotation (4°), Internal rotation score (0.2). SCB thresholds for the overall cohort were: VAS Pain (-3.3), SFS (2.9), SST 3.8), Constant (18.9), ASES (33.1), UCLA (12.3), SPADI (-44.7), and SAS (18.2), Abduction (30°), Forward elevation (31°), External rotation (12°), Internal rotation score (0.9). PASS thresholds for the overall cohort were: VAS Pain (0.8), SFS (7.3), SST (9.2), Constant (64.2), ASES (79.5), UCLA (29.5), SPADI (24.7), and SAS (72.5), Abduction (104°), Forward elevation (130°), External rotation (30°), Internal rotation score (3.2). MCID, SCB, and PASS thresholds varied depending on preoperative diagnosis and sex. CONCLUSION: MCID, SCB, and PASS thresholds vary depending on implant type, preoperative diagnosis, and sex. A comprehensive understanding of these differences as well as identification of clinically relevant thresholds for legacy and novel metrics is essential to assist surgeons in evaluating their patient's outcomes, interpreting the literature, and counseling their patients preoperatively regarding expectations for improvement. Given that PASS thresholds are fragile and vary greatly depending on cohort variability, caution should be exercised in conflating them across different studies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Hospital for Special Surgery, West Palm Beach, FL, USA.
- Exactech, Inc., Gainesville, FL, USA.
- NYU Langone Orthopedic Hospital, New York, NY, USA.
- Department of Orthopaedic Surgery & Sports Medicine, University of Florida, Gainesville, FL, USA.
- Medical University of South Carolina, Charleston, SC, USA.
- Department of Orthopaedic Surgery, Clinique du Sport de Bordeaux-Mérignac, Mérignac, France.
Zitieren
APA
Simovitch, R. W., Elwell, J., Colasanti, C. A., Hao, K. A., Friedman, R. J., Flurin, P. H., Wright, T. W., Schoch, B. S., Roche, C. P., & Zuckerman, J. D. (2024). Stratification of the minimal clinically important difference, substantial clinical benefit, and patient acceptable symptomatic state after total shoulder arthroplasty by implant type, preoperative diagnosis, and sex. Journal of Shoulder and Elbow Surgery, 33(9), e492-e506. https://doi.org/10.1016/j.jse.2024.01.040
Vancouver
Simovitch RW, Elwell J, Colasanti CA, Hao KA, Friedman RJ, Flurin PH, et al. Stratification of the minimal clinically important difference, substantial clinical benefit, and patient acceptable symptomatic state after total shoulder arthroplasty by implant type, preoperative diagnosis, and sex. Journal of Shoulder and Elbow Surgery. 2024;33(9):e492-e506. doi:10.1016/j.jse.2024.01.040
BibTeX
@article{Simovitch2024,
author = {Simovitch, Ryan W and Elwell, Josie and Colasanti, Christopher A and Hao, Kevin A and Friedman, Richard J and Flurin, Pierre-Henri and Wright, Thomas W and Schoch, Bradley S and Roche, Christopher P and Zuckerman, Joseph D},
title = {Stratification of the minimal clinically important difference, substantial clinical benefit, and patient acceptable symptomatic state after total shoulder arthroplasty by implant type, preoperative diagnosis, and sex},
journal = {Journal of Shoulder and Elbow Surgery},
year = {2024},
volume = {33},
number = {9},
pages = {e492--e506},
doi = {10.1016/j.jse.2024.01.040}
}
EUVIMED